Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Blindness secondary to prostate cancer.

Literature DB >> 8149144

Blindness secondary to prostate cancer.

Abstract

We report a case of blindness, secondary to hormone-refractory prostate cancer, occurring 7 years after the diagnosis of metastatic prostate cancer and 3.5 years after the clinical onset of the hormone-refractory state. Prolonged suppression of the disease with chemotherapy may have contributed to the unusual clinical findings. We discuss the role of supportive care in the management of prostate cancer.

Entities: Disease

Mesh：

Year: 1993 PMID： 8149144 DOI： 10.1007/bf00366063

Source DB: PubMed Journal: Support Care Cancer ISSN： 0941-4355 Impact factor: 3.603

13 in total

Review 1. Second line treatment of hormone refractory prostatic cancer patients.

Authors: L G Collste
Journal: Prog Clin Biol Res Date: 1990

Review 2. Brain metastasis from prostatic cancer.

Authors: D P Sarma; L Godeau
Journal: J Surg Oncol Date: 1983-07 Impact factor: 3.454

3. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.

Authors: C K Osborne; B Blumenstein; E D Crawford; C A Coltman; A Y Smith; B W Lambuth; R A Chapman
Journal: J Clin Oncol Date: 1990-10 Impact factor: 44.544

4. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

Authors: H I Scher; T Curley; N Geller; C Engstrom; D D Dershaw; S Y Lin; K Fitzpatrick; J Nisselbaum; M Schwartz; L Bezirdjian
Journal: J Clin Oncol Date: 1990-11 Impact factor: 44.544

Blindness secondary to prostate cancer.

Review 1. Second line treatment of hormone refractory prostatic cancer patients.

Review 2. Brain metastasis from prostatic cancer.

3. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study.

4. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

5. Parenchymal brain metastases from adenocarcinoma of prostate.

6. Cranial nerve lesions due to base of the skull metastases in prostate carcinoma.

7. Metastasis to the base of the skull: clinical findings in 43 patients.

8. Intracranial metastases in prostate cancer.

9. Cranial nerve dysfunction in metastatic cancer of the prostate.

10. Cranial nerve involvement with carcinoma of prostate.

Review 1. Cystic prostate metastases to the brain parenchyma: report of two cases and review of the literature.